SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is rallying on its announcement that SoFi Bank has gone live with stablecoin settlement (SoFiUSD) across Mastercard's global payments network, which the company bills as a first among U.S. national banks. The community is split: bulls tout the partnership as a long-term payments-infrastructure catalyst and hope for a short squeeze, while bears expect the pop to fade, citing the stock's pattern of selling off intraday rallies, prior dilution, and rate-hike headwinds.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics shares are trending following positive topline results from a maintenance study of its obesity drug, VK2735, which demonstrated strong weight-loss maintenance and high tolerability. The community is actively debating the stock's valuation and the potential for a takeover or partnership, with many traders speculating on a bidding war while others express skepticism regarding timing and dilution risks.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending ahead of its earnings report, with sentiment driven by an analyst note predicting strong revenue and EPS beats, alongside excitement regarding a new design win for its Alloy Kore automotive software. The community is actively debating the company's growth prospects, with many traders expressing bullish sentiment despite ongoing concerns about short-term volatility and market manipulation.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

XNDU is trending on a sharp selloff that traders are attributing to a share unlock and unusually heavy short-selling pressure. Posts claim short interest runs as high as 68% of the float  an unverified figure  and the community is sharply divided. Bears call the pre-revenue photonic quantum computing company an easy short, argue its valuation is far too high for its revenue base, and dismiss recent press releases, including a photonic chip packaging milestone and a roughly $800K Mitsubishi Chemical collaboration, as non-revenue news that cannot support the stock. Bulls counter that Xanadu's record CAD $195 million in government-backed funding gives it multiple years of runway, cite partnerships with ASML, Lockheed Martin, and Mitsubishi Chemical as validation of its technology, and argue the heavy short positioning sets up a squeeze, with some traders linking the weakness to skepticism about a potential CAD $300 million+ Canadian government grant. Many in the community are also watching an upcoming earnings call as the next test of the company's claims.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft's draft AI code of conduct and its role in a coordinated AI-safety push with other AI labs are driving the conversation. The confirmed policy proposal would require future in-house models to accept correction, never resist shutdown, and communicate intelligibly with humansformalizing human-control requirements at the model-training level. Reaction is split: some traders frame it as responsible governance and a bull case, echoed by analyst target hikes tied to the AI-safety debate (Citizens at $550, Redburn at $440), while skeptics speculate the safety framing is a pretext for cost containment, citing Foundry's substantial losses, borrowing to fund hyperscale AI projects, and strained datacenter energy supply. Related headlinesAltman ruling out an OpenAI IPO over safety concerns and Zuckerberg favoring lab-by-lab decisions on slowing developmentfuel debate over whether this is genuine safety policy or a brake on AI investment. Others question the stock's muted reaction, and some traders speculate it is being supported to prop up the broader market.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as traders react to the company's Capital Markets Day, where plans for future multi-blockbuster launches and an increased emphasis on oral GLP-1 therapies failed to satisfy investor concerns regarding competition from Eli Lilly and the upcoming patent expiration for Semaglutide. While some investors view the stock as undervalued and point to improving fundamentals, others remain bearish, highlighting the lack of clear near-term catalysts and management's failure to boost investor confidence.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

The conversation centers on the iPhone 18 Pro's retail launch and the stock's push toward record highs, with demand sharply debated: bulls point to long store lines, reported sellouts in China and larger carrier trade-in promotions, while bears counter with reports of shorter wait times, premium pricing and heavy put buying. Analyst price-target hikes tied to a better-than-expected iPhone refresh cycle, along with anticipation for the upcoming foldable iPhone Duo, support the bullish side of the debate.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending following a strong second-quarter earnings report that featured a revenue beat and robust third-quarter growth guidance, fueling optimism about its ability to monetize AI-driven commerce. While bullish investors celebrate the stock's significant price surge and the company's solid fundamentals, some traders remain skeptical, debating the sustainability of the move and questioning the long-term impact of AI on the company's moat.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending after a quarterly report that came in far above expectations, with YARTEMLEA launch momentum, an operating breakeven, and convertible-debt reduction driving the stock to multi-year highs. Traders are leaning into short-squeeze and valuation re-rating talk while debating insider option sales and watching upcoming catalysts such as the EU re-examination of Yartemlea, the start of NTAP Medicare reimbursement, and a potential Novo Nordisk milestone payment.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly's obesity and GLP-1 franchise is driving the conversation, with attention spread across several related developments rather than one single event. Traders are weighing retatrutide (Foundayo) developments  data presentations planned in Europe, accompanied by a circulating Berenberg note citing roughly 21% potential upside, plus Lilly's lawsuits against compounders selling retatrutide through the black market  alongside the reported ~$2.85B acquisition of Merida Biosciences and new Phase 3b Taltz data, including early Taltz-Zepbound combination findings. One trader characterized the stock's pullback as an overreaction to the Merida deal, while others attributed the dip to broader market and healthcare-sector weakness plus profit-taking. Posts also flagged UK authorization of Lilly's oral obesity pill as expanding its addressable market, and a study linking Zepbound use to lower healthcare costs in adults over 55. The sharpest debate is competitive positioning: one detailed argument holds that Lilly and Novo Nordisk are competing in an underpenetrated, expanding obesity market rather than a fixed patient pool  "never short the GLP market"  while other traders counter that Novo is outperforming on oral GLP-1s and that Viking's VK2735 could credibly challenge Lilly within 1218 months. Scattered posts add speculation about a stock split following strong earnings, buyouts of smaller biotechs, and Lilly's trillion-dollar valuation, but these reflect individual views rather than consensus.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


thaonhile19

Thảo Nhi